Which HPLC system-suitability fields should you read first on a peptide COA?
Start by linking the COA to the received lot and the supporting analytical record. A COA may summarise results rather than reproduce the complete sequence, method and SST evidence. Missing information on the certificate is a reason to request supporting records, not automatic proof that the analysis was invalid.
Record the method identifier and version, analysis date, sequence identifier and sample or result identifier where available. Review relevant method conditions, including column specification, detection settings and processing-method version. If the method version is unavailable, comparability between lots cannot be established from the certificate alone. Different methods may still be comparable where an appropriate bridging assessment exists.
Identify the SST material and its role under the method. A reference material, in-house standard or sample-derived preparation may be appropriate for particular checks, but these materials are not automatically interchangeable. A sample-derived preparation is not an independent identity reference.
Review each required SST result against its approved method criterion. Depending on the method, these checks may include replicate response precision, retention behaviour, plate count, peak shape or resolution of a specified pair. Not every method requires every parameter, and acceptance criteria may be held in a controlled method or supporting report rather than printed on the COA.
Confirm that the SST evidence applies to the sample sequence under the method's rules, including any requirements following interruptions or system changes. Record authorisation or review details according to the laboratory's document-control procedures.
What do tailing, plate count and resolution establish?
Peak shape, efficiency and resolution help assess chromatographic performance, but passing these checks does not demonstrate that every component in a sample has been separated.
Tailing factor and symmetry factor describe peak shape using different conventions. Record which calculation is reported and compare it only with the corresponding method criterion. Poor peak shape can make integration and the detection of nearby components more difficult.
Theoretical plate count (N) measures efficiency for a particular peak under particular conditions. It depends on the analyte, method and calculation convention. Do not transfer a plate-count limit from an unrelated method or infer that a high N excludes co-elution.
Resolution (Rs) measures separation for a defined peak pair. Identify that pair and its role in the method. Passing resolution for one pair does not establish separation from unknown impurities. Conversely, the absence of an Rs field is not automatically a failure if the method uses other justified suitability criteria.
Retention factor, sometimes called capacity factor, may be useful where the method specifies it and provides a suitable estimate of hold-up time. It is not a universal COA requirement.
If an applicable SST criterion fails, flag the affected results for laboratory investigation and disposition under the method and quality procedures. Do not accept a result merely because other parameters passed. SST supports system performance; method specificity and other evidence are needed to assess what the reported result means.
How should bracketing standards and area RSD be reviewed?
Where the method requires bracketing standards, use the sequence table to locate the specified injections before, during or after the sample set. Their purpose and frequency should come from the method rather than an assumed universal sequence design.
Distinguish initial replicate-injection precision from continuing or bracketing checks. A method may use relative standard deviation (RSD), response differences, retention-time limits or another defined measure. Confirm which injections enter the calculation, their concentrations and any normalisation applied.
An out-of-limit response may reflect injection variability, preparation differences, solution instability, integration changes or instrument behaviour. RSD alone does not identify the cause. Nor does variation in absolute standard response necessarily produce the same change in a within-chromatogram area-percentage result. Assess its relevance under the method.
Retention-time agreement can support a chromatographic assignment under specified conditions, but it is not unique proof of identity. Investigate unexpected shifts using the method and supporting records.
Distinguish area-percent purity from an assay. Area percentage expresses a peak's integrated response relative to the included peak responses under the stated method. It is not necessarily a mass fraction and may not capture water, counter-ions, residual solvents, non-detected components or differences in detector response. An assay estimates content against a defined reference or calibration approach on a stated reporting basis. Corrections depend on the method; they are not automatic. Assay and area-percentage values can coincide, but they are not interchangeable.
Check that standards and samples were processed using the appropriate controlled settings. Identical settings are not universally required for different injection types, but differences affecting interpretation should be documented.
How do blanks and unidentified peaks affect interpretation?
Blank injections can help investigate background signals, contamination and carry-over. They may form part of SST or other sequence controls, depending on the method. A solvent blank and a preparation blank address different possible sources of interference.
Review the blank composition, its position in the sequence and its relationship to the sample preparation. When inspecting chromatograms, account for differences in scale, injection volume, processing and preparation. A visually flat trace at a compressed scale is not enough to establish the absence of relevant interference.
Apply the method's blank-interference and carry-over criteria. These are not necessarily the same as the reporting threshold for sample impurities. A blank following a high-response injection can assess carry-over, but an ordinary solvent injection is not automatically a complete carry-over assessment.
A peak appearing in both blank and sample may have a background contribution, a sample contribution or both. Do not automatically classify it as a sequence artefact or subtract it from a related-substance total. Attribution and any correction require a justified procedure and supporting evidence.
If relevant blank evidence is absent from the supplied pack, record that the receiving laboratory cannot independently assess those controls from the available documents. Request the supporting records rather than assuming the controls were not performed.
A clean blank does not establish identity. Orthogonal evidence may be needed for the identity claim being made. Intact-mass data can support an expected molecular-mass assignment, but generally cannot establish a unique sequence or distinguish all isomeric materials.
Which identifiers establish peptide lot traceability?
Build a documented crosswalk from the received container to the COA, the laboratory sample and the analytical result. The identifiers do not need to be textually identical if a controlled mapping connects them without ambiguity.
Record the supplier or manufacturer lot code, catalogue identifier, COA identifier and issue or revision date. Capture the received container identifier where one exists. Then map these to the laboratory accession or sample identifier, preparation record, sequence identifier, injection or vial position, result identifier and raw-data reference.
A generic sample name alone is insufficient to establish the link, but a lot code does not have to appear in the chromatography data system's sample-name field if a controlled accession or sample-preparation record provides that link. File names and result identifiers are useful references; they are not inherently unique or durable without suitable data controls.
Distinguish a shipping container from an autosampler vial. When a result represents a shared lot, the record should describe how the analytical sample was taken and which lot or containers it represents. A batch-level result is not automatically evidence that every individual container was analysed.
Order references and tracking identifiers support fulfilment traceability. They do not, by themselves, complete chain of custody or demonstrate analytical sample provenance. Depending on the laboratory's requirements, the record may also need receipt details, transfers, sampling and subsampling records, storage conditions and relevant repackaging history. A statement of Australian stock location is not an analytical identity control.
Keep a local review worksheet containing the received lot identifier, COA version, accession or sample identifier, method version, sequence and result references, applicable SST status, blank-review observations, reported result and reporting basis, outstanding questions and review disposition. Link identity evidence appropriate to the stated claim. Compare later lots only after considering method comparability, sampling and the basis of each reported result.
Apply this checklist to documented stock
You now have a practical way to read purity figures, method notes, and lot traceability. When you source materials, hold suppliers to that same checklist — ClaraScience issues batch documentation with every order and dispatches from Australian warehouses with Express tracked shipping.
Start with a retail order to review documentation end-to-end, or register for wholesale if you restock multiple compounds.
Frequently asked questions
Why review HPLC system suitability before interpreting a purity percentage?
SST helps establish whether the system met the method's specified performance criteria for the relevant analysis. Review the applicable criteria and results before relying on the sample result. Passing SST does not prove identity, exclude all co-elution or establish lot traceability on its own.
What if the COA lists SST numbers but no acceptance criteria?
Request the controlled method criteria or a supporting suitability report. Criteria need not appear on the certificate itself, but the reviewer needs access to the applicable limits and results to assess conformity. Do not borrow limits from another method.
Are blank chromatograms part of peptide lot traceability?
Blanks support interpretation of the analytical evidence attached to a lot; they do not establish the lot-to-sample link themselves. Link relevant blank records to the sequence and review them against the method's interference or carry-over requirements. If they are not supplied, record the review limitation and request them where needed.
Must the lot code appear in the HPLC sample name?
No. The lot must be unambiguously linked to the analytical sample and result, but a controlled accession record or identifier crosswalk can provide that connection. For results representing multiple containers from one lot, verify the sampling record and the scope of the result rather than expecting a separate injection for every received container.
Does passing SST or matching intact mass prove peptide identity?
Neither establishes a unique identity on its own. SST concerns chromatographic performance. Intact mass can support consistency with an expected molecular mass, but it may not distinguish sequence isomers or other isobaric materials. The necessary identity evidence depends on the material, method and claim.
Do Australian dispatch records complete chain of custody?
No. Tracking records connect fulfilment events, but analytical traceability also depends on documented receipt, sample provenance, sampling and any relevant transfers or repackaging. Local stock status does not establish analytical validity or regulatory approval.
References
- DOI:10.1002/asi.5090180408 — Suggestions on how to read experimental material in information science — American Documentation — 1967
- DOI:10.5694/j.1326-5377.1992.tb137249.x — 13. How to read a journal article — Medical Journal of Australia — 1992
- DOI:10.1006/abio.1993.1102 — The Direct Assay of Kinases and Acyl-CoA Synthetases by HPLC: Application to Nucleoside Diphosphate Kinase and Succinyl-CoA Synthetase — Analytical Biochemistry — 1993
- DOI:10.3897/tdwgproceedings.1.19941 — Documentation about Atlas of Living Australia tools: how to find information — Proceedings of TDWG — 2017
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
